Therapeutic Category, dog
1H-Indole-2-carboxamide, 1-methyl-N-[(1S)-2-[methyl(phenylmethyl)amino]-2-oxo-1-phenylethyl]-5-[[[4′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]carbonyl]amino]- (USAN)
5-[4′-(Trifluoromethylbiphenyl-2-carbonyl)amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide
Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.
It works as a selective microsomal triglyceride transfer protein (MTTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.
It is supplied as an oral solution. It is not intended for use in humans, cats, or parrots.
Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog’s weight.
Canine patient information sheet http://www.drsfostersmith.com/Rx_Info_Sheets/rx_dirlotapide.pdf
- “FDA approves 1st drug for obese dogs”. Yahoo. Archived from the original on January 8, 2007. Retrieved 2007-01-06.
- Dirlotapide (OS: USAN)
- CP-742033 (IS)
- Slentrol (veterinary use)
Pfizer, Poland; Pfizer Animal Health, Belgium; Pfizer Animal Health, Switzerland; Pfizer Animal Health, United Kingdom; Pfizer Animal Health, United States; Pfizer GmbH Tiergesundheit, Germany; Pfizer Limited, Austria; Pfizer Santé Animale, France